南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停
南美超级胎牛血清999尝鲜特惠
转染试剂低至5折
基质胶阶梯特惠
积分商城,好礼送不停

双靶向TROP2和PERK抑制Wnt/β-catenin信号克服晚期结直肠癌ADC耐药

Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling

Jie Liu, Mei Li, Jianming Huang, Yujie Xia, Guanfeng Jiang, Hong’an Zhang, Jiaxin Yang, Mingfeng Jiang, Yalan Liu, Yilun Luo, Liefeng Wang, Shuyong Zhang

Journal:Cell Reports Medicine

IF:14

DOI:10.1016/j.xcrm.2026.102769

PMID:42030933

Published:2026-04-23

research field:肿瘤学分子生物学靶向治疗信号转导癌症药理学

Abstract

Targeted therapy for advanced colorectal cancer (CRC) remains a significant unmet clinical need. Here, we investigate the mechanism of the anti-TROP2 antibody-drug conjugate IMMU132, delivering SN-38 to induce TOP1-mediated DNA damage and cytotoxicity. We further discover that it concurrently suppresses the PERK-eIF2α-ATF4 axis of the unfolded protein response, a key adaptive survival pathway activated by therapy-induced endoplasmic reticulum (ER) stress. This dual action of direct killing and stress adaptation disruption may dismantle a key resistance mechanism. Furthermore, combining IMMU132 with the PERK inhibitor GSK2606414 yields potent synergy across various CRC preclinical models. Mechanistically, this synergy stems from the enhanced suppression of ER stress and the oncogenic Wnt/β-catenin pathway. Thus, our findings reveal that co-targeting the DNA damage response, the PERK pathway, and the Wnt/β-catenin pathway is a promising strategy to overcome resistance to TROP2-directed antibody-drug conjugates (ADCs) in advanced CRC, providing a rational framework for combination therapies.

本文使用的Yeasen产品

购物车
客服
转染试用